The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2021 | SARS-CoV-2 in multiple myeloma
Multiple myeloma affects adaptive immunity with neoplastic plasma cells being unable to manufacture the polyclonal immunoglobulins required to fight infections. Additionally, myeloma treatment can raise immunodeficiency, especially during the initial months of treatment or during relapsed disease. In this video, Krina Patel, MD, MSc, MD Anderson Cancer Center, Houston, TX, talks on SARS-CoV-2 in multiple myeloma, highlighting strategies to mitigate negative outcomes. This interview took place during the 2nd Immune Effector Cell Therapy in MM Workshop in Boston, MA.
